DK2868660T3 - Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse - Google Patents
Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelseInfo
- Publication number
- DK2868660T3 DK2868660T3 DK13813275.8T DK13813275T DK2868660T3 DK 2868660 T3 DK2868660 T3 DK 2868660T3 DK 13813275 T DK13813275 T DK 13813275T DK 2868660 T3 DK2868660 T3 DK 2868660T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- atom
- substituent
- alkoxy
- effect potentiator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012148850 | 2012-07-02 | ||
JP2012215902 | 2012-09-28 | ||
PCT/JP2013/068054 WO2014007217A1 (ja) | 2012-07-02 | 2013-07-01 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2868660T3 true DK2868660T3 (da) | 2018-01-29 |
Family
ID=49881973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13813275.8T DK2868660T3 (da) | 2012-07-02 | 2013-07-01 | Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse |
Country Status (14)
Country | Link |
---|---|
US (1) | US9375434B2 (da) |
EP (1) | EP2868660B1 (da) |
JP (1) | JP5855250B2 (da) |
KR (2) | KR20160128456A (da) |
AU (1) | AU2013284570B2 (da) |
DK (1) | DK2868660T3 (da) |
ES (1) | ES2660215T3 (da) |
HU (1) | HUE036188T2 (da) |
NO (1) | NO2868660T3 (da) |
PL (1) | PL2868660T3 (da) |
PT (1) | PT2868660T (da) |
RU (1) | RU2618423C2 (da) |
TW (1) | TWI534149B (da) |
WO (1) | WO2014007217A1 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3012327T (pt) * | 2013-06-20 | 2021-01-22 | Taiho Pharmaceutical Co Ltd | Método para prever a eficácia terapêutica do inibidor de pi3k/akt/mtor com base na expressão de phlda1 ou pik3c2b |
US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
TR201907147T4 (tr) | 2013-07-18 | 2019-06-21 | Taiho Pharmaceutical Co Ltd | Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç. |
EP3263573B1 (en) | 2015-02-27 | 2019-12-04 | Taiho Pharmaceutical Co., Ltd. | Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal |
EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR TREATING MALIGNANT TUMORS |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
AU2019239404B2 (en) | 2018-03-19 | 2021-12-23 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
AU2020297166A1 (en) * | 2019-06-21 | 2022-02-17 | Taiho Pharmaceutical Co., Ltd. | Method for treating malignant tumor |
BR112022021631A2 (pt) | 2020-04-28 | 2022-12-06 | Basf Se | Compostos, composição, métodos para combater ou controlar pragas invertebradas, para proteger plantas em crescimento e para tratar ou proteger um animal, semente e uso de um composto |
CN118302417A (zh) * | 2021-08-25 | 2024-07-05 | Ptc医疗公司 | Nlrp3抑制剂 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007282535B9 (en) * | 2006-08-08 | 2013-06-20 | Chugai Seiyaku Kabushiki Kaisha | Pyrimidine derivative as PI3K inhibitor and use thereof |
AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
DE602008005894D1 (de) * | 2007-08-14 | 2011-05-12 | Bayer Schering Pharma Ag | Kondensierte imidazole zur krebsbehandlung |
US9451809B2 (en) | 2008-05-29 | 2016-09-27 | Nike, Inc. | Article of footwear with a marking system |
JP2011522048A (ja) | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
US20110288090A1 (en) | 2009-02-02 | 2011-11-24 | Armstrong Donna J | Inhibitors of AKT Activity |
EP2403339B1 (en) | 2009-03-06 | 2017-01-18 | Merck Sharp & Dohme Corp. | Combination cancer therapy with an akt inhibitor and other anticancer agents |
WO2010104933A1 (en) | 2009-03-11 | 2010-09-16 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
EP2698372B1 (en) * | 2011-04-06 | 2016-02-03 | Taiho Pharmaceutical Co., Ltd. | Novel imidazo-oxazine compound or salt thereof |
-
2013
- 2013-07-01 RU RU2015103151A patent/RU2618423C2/ru active
- 2013-07-01 TW TW102123523A patent/TWI534149B/zh active
- 2013-07-01 AU AU2013284570A patent/AU2013284570B2/en active Active
- 2013-07-01 DK DK13813275.8T patent/DK2868660T3/da active
- 2013-07-01 US US14/407,745 patent/US9375434B2/en active Active
- 2013-07-01 PL PL13813275T patent/PL2868660T3/pl unknown
- 2013-07-01 KR KR1020167030063A patent/KR20160128456A/ko not_active Application Discontinuation
- 2013-07-01 KR KR1020157001880A patent/KR101671761B1/ko active IP Right Grant
- 2013-07-01 JP JP2014523736A patent/JP5855250B2/ja active Active
- 2013-07-01 WO PCT/JP2013/068054 patent/WO2014007217A1/ja active Application Filing
- 2013-07-01 EP EP13813275.8A patent/EP2868660B1/en active Active
- 2013-07-01 NO NO13813275A patent/NO2868660T3/no unknown
- 2013-07-01 ES ES13813275.8T patent/ES2660215T3/es active Active
- 2013-07-01 PT PT138132758T patent/PT2868660T/pt unknown
- 2013-07-01 HU HUE13813275A patent/HUE036188T2/hu unknown
Also Published As
Publication number | Publication date |
---|---|
HUE036188T2 (hu) | 2018-06-28 |
TW201408671A (zh) | 2014-03-01 |
WO2014007217A1 (ja) | 2014-01-09 |
PT2868660T (pt) | 2018-02-02 |
TWI534149B (zh) | 2016-05-21 |
NO2868660T3 (da) | 2018-05-26 |
US20150164909A1 (en) | 2015-06-18 |
PL2868660T3 (pl) | 2018-05-30 |
KR20150023870A (ko) | 2015-03-05 |
EP2868660B1 (en) | 2017-12-27 |
US9375434B2 (en) | 2016-06-28 |
RU2618423C2 (ru) | 2017-05-03 |
AU2013284570B2 (en) | 2016-04-14 |
EP2868660A4 (en) | 2016-03-23 |
EP2868660A1 (en) | 2015-05-06 |
KR20160128456A (ko) | 2016-11-07 |
RU2015103151A (ru) | 2016-08-20 |
KR101671761B1 (ko) | 2016-11-02 |
AU2013284570A1 (en) | 2015-01-22 |
JPWO2014007217A1 (ja) | 2016-06-02 |
ES2660215T3 (es) | 2018-03-21 |
JP5855250B2 (ja) | 2016-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2868660T3 (da) | Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse | |
PH12016501535A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
PH12016501813B1 (en) | 1,3-benzodioxole derivative | |
WO2013100566A8 (en) | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | |
MX2013011429A (es) | Novedoso compuesto de imidazo-oxazina o sal del mismo. | |
EA201390885A1 (ru) | Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса | |
PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
IN2015MN00405A (da) | ||
MX2015012062A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
EA201390884A1 (ru) | Азабензимидазолы в качестве противовирусных средств в отношении респираторного синцитиального вируса | |
MX2014011829A (es) | Compuestos de piridinilideno n-sustituidos y derivados para combatir plagas de animales. | |
MX2014000452A (es) | Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk). | |
MY196172A (en) | Tricyclic Spiro Compound | |
MX2012002528A (es) | Agente terapeutico para trastornos del estado de animo. | |
EA201491525A1 (ru) | Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae | |
MX364207B (es) | Inhibidores de agrecanasa. | |
IN2014MN02485A (da) | ||
BR112013015774A2 (pt) | compostos de pirazol tendo efeito terapêutico sobre mieloma múltiplo. | |
PH12016500152A1 (en) | Novel triazine derivative | |
MX343077B (es) | Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos. | |
AR092772A1 (es) | Derivado de 7-azaindol | |
PH12015501056A1 (en) | 2-pyridone compound | |
MX2012002529A (es) | Agente terapeutico para trastornos de ansiedad. | |
WO2013062332A3 (ko) | 시링가레시놀을 포함하는 혈관 노화 억제용 조성물 | |
MX358494B (es) | Derivado de acido pirrolidin-3-ilacetico. |